Evidence map›Paper›PMID 35267535›Full record

ArticleCancers2022

Multitask Learning Radiomics on Longitudinal Imaging to Predict Survival Outcomes following Risk-Adaptive Chemoradiation for Non-Small Cell Lung Cancer.

Parisa Forouzannezhad, Dominic Maes, Daniel S Hippe, Phawis Thammasorn, Reza Iranzad, Jie Han, Chunyan Duan, Xiao Liu, Shouyi Wang, W Art Chaovalitwongse and 2 more

Registry-linked trialAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02773238 (Personalized Radiation Therapy Through Functional Lung Avoidance and Response-Adaptive Dose Escalation), which is not on this map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02773238 phase2completednot on this map

Personalized Radiation Therapy Through Functional Lung Avoidance and Response-Adaptive Dose Escalation: Utilizing Multimodal Molecular Imaging to Improve the Therapeutic Ratio (FLARE RT)

TypeinterventionalSponsorUniversity of WashingtonRan2016 to 2023Enrolled51ConditionsStage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7ArmsComputed Tomography, Fludeoxyglucose F-18, Laboratory Biomarker Analysis, Positron Emission Tomography, Radiation Therapy
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Parisa ForouzannezhadDepartment of Radiation Oncology, School of Medicine, University of Washington, Seattle, WA 98195, USA.
Dominic MaesDepartment of Radiation Oncology, School of Medicine, University of Washington, Seattle, WA 98195, USA.
Daniel S HippeClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0003-2427-4404
Phawis ThammasornDepartment of Industrial Engineering, University of Arkansas, Fayetteville, AR 72701, USA.
Reza IranzadDepartment of Industrial Engineering, University of Arkansas, Fayetteville, AR 72701, USA.
Jie HanDepartment of Industrial, Manufacturing, and System Engineering, University of Texas, Arlington, TX 76019, USA.
Chunyan DuanDepartment of Mechanical Engineering, Tongji University, Shanghai 200092, China.
Xiao LiuDepartment of Industrial Engineering, University of Arkansas, Fayetteville, AR 72701, USA.
Shouyi WangDepartment of Industrial, Manufacturing, and System Engineering, University of Texas, Arlington, TX 76019, USA.
W Art ChaovalitwongseDepartment of Industrial Engineering, University of Arkansas, Fayetteville, AR 72701, USA.
Jing ZengDepartment of Radiation Oncology, School of Medicine, University of Washington, Seattle, WA 98195, USA.
Stephen R BowenDepartment of Radiation Oncology, School of Medicine, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0001-7581-770X

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Biomarkers of Response to Immuno-chemotherapy & oliGometastatic Hypofractionated radioTherapy (BRIGHT) for Lung Cancer: Synergy of PET/CT Imaging and Peripheral Blood AssaysR01CA258997 · NCI · UNIVERSITY OF WASHINGTON · PI Stephen R. Bowen, Jing Zeng · 2022 to 2026
$2.8M
Personalized radiation therapy through functional lung avoidance and response-adaptive dose escalation: utilizing multimodal molecular imaging to improve the therapeutic ratioR01CA204301 · NCI · UNIVERSITY OF WASHINGTON · PI BOWEN, STEPHEN R., ZENG, JING · 2016 to 2020
$2.3M
NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA204301NCI NIH HHS R01 CA258997NIH HHS R01CA204301, R01CA258997, P30CA015704
6 · The paper itself

Abstract

Medical imaging provides quantitative and spatial information to evaluate treatment response in the management of patients with non-small cell lung cancer (NSCLC). High throughput extraction of radiomic features on these images can potentially phenotype tumors non-invasively and support risk stratification based on survival outcome prediction. The prognostic value of radiomics from different imaging modalities and time points prior to and during chemoradiation therapy of NSCLC, relative to conventional imaging biomarker or delta radiomics models, remains uncharacterized. We investigated the utility of multitask learning of multi-time point radiomic features, as opposed to single-task learning, for improving survival outcome prediction relative to conventional clinical imaging feature model benchmarks. Survival outcomes were prospectively collected for 45 patients with unresectable NSCLC enrolled on the FLARE-RT phase II trial of risk-adaptive chemoradiation and optional consolidation PD-L1 checkpoint blockade (NCT02773238). FDG-PET, CT, and perfusion SPECT imaging pretreatment and week 3 mid-treatment was performed and 110 IBSI-compliant pyradiomics shape-/intensity-/texture-based features from the metabolic tumor volume were extracted. Outcome modeling consisted of a fused Laplacian sparse group LASSO with component-wise gradient boosting survival regression in a multitask learning framework. Testing performance under stratified 10-fold cross-validation was evaluated for multitask learning radiomics of different imaging modalities and time points. Multitask learning models were benchmarked against conventional clinical imaging and delta radiomics models and evaluated with the concordance index (c-index) and index of prediction accuracy (IPA). FDG-PET radiomics had higher prognostic value for overall survival in test folds (c-index 0.71 [0.67, 0.75]) than CT radiomics (c-index 0.64 [0.60, 0.71]) or perfusion SPECT radiomics (c-index 0.60 [0.57, 0.63]). Multitask learning of pre-/mid-treatment FDG-PET radiomics (c-index 0.71 [0.67, 0.75]) outperformed benchmark clinical imaging (c-index 0.65 [0.59, 0.71]) and FDG-PET delta radiomics (c-index 0.52 [0.48, 0.58]) models. Similarly, the IPA for multitask learning FDG-PET radiomics (30%) was higher than clinical imaging (26%) and delta radiomics (15%) models. Radiomics models performed consistently under different voxel resampling conditions. Multitask learning radiomics for outcome modeling provides a clinical decision support platform that leverages longitudinal imaging information. This framework can reveal the relative importance of different imaging modalities and time points when designing risk-adaptive cancer treatment strategies.

Indexed as

CTFDG-PETgradient boostingLASSOlung cancermultimodal imagingmultitask regressionradiomicsSPECTsurvival analysis

Identifiers

PMID35267535
PMCPMC8909466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.